Robert I Blum Cytokinetics Inc (CYTK) insider trading activity

Robert I Blum is President & CEO of CYTOKINETICS INC. Currently has a direct ownership of 422,629 shares of CYTK, which is worth approximately $16.7 Million. The most recent transaction as insider was on Nov 02, 2022, when has been sold 10,000 shares (Common Stock) at a price of $8.81 per share, resulting in proceeds of $88,100. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 423K

4.78% 3M change

8.37% 12M change

Total Value Held $16.7 Million

Robert I Blum Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 02 2022	BUY Exercise of conversion of derivative security	$88,100 $8.81 p/Share	10,000 Added 2.4%	406,881 Common Stock
Oct 19 2022	SELL Open market or private sale	$478,600 $47.86 p/Share	10,000 Reduced 2.4%	406,089 Common Stock
Oct 19 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.35%	416,089 Common Stock
Oct 03 2022	SELL Open market or private sale	$504,000 $50.4 p/Share	10,000 Reduced 2.4%	406,089 Common Stock
Oct 03 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.35%	416,089 Common Stock
Sep 19 2022	SELL Open market or private sale	$514,200 $51.42 p/Share	10,000 Reduced 2.4%	406,089 Common Stock
Sep 19 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.35%	416,089 Common Stock
Sep 07 2022	SELL Open market or private sale	$491,100 $49.11 p/Share	10,000 Reduced 2.4%	406,089 Common Stock
Sep 07 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.35%	416,089 Common Stock
Aug 17 2022	SELL Open market or private sale	$501,100 $50.11 p/Share	10,000 Reduced 2.39%	409,124 Common Stock
Aug 17 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.33%	419,124 Common Stock
Aug 01 2022	SELL Open market or private sale	$412,600 $41.26 p/Share	10,000 Reduced 2.39%	409,124 Common Stock
Aug 01 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.33%	419,124 Common Stock
Jul 18 2022	SELL Open market or private sale	$404,900 $40.49 p/Share	10,000 Reduced 2.38%	409,472 Common Stock
Jul 18 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.33%	419,472 Common Stock
Jul 06 2022	SELL Open market or private sale	$443,800 $44.38 p/Share	10,000 Reduced 2.38%	409,472 Common Stock
Jul 06 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.33%	419,472 Common Stock
Jun 15 2022	SELL Open market or private sale	$394,000 $39.4 p/Share	10,000 Reduced 2.38%	409,472 Common Stock
Jun 15 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.33%	419,472 Common Stock
Jun 06 2022	SELL Open market or private sale	$412,300 $41.23 p/Share	10,000 Reduced 2.38%	409,472 Common Stock
Jun 06 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.33%	419,472 Common Stock
May 16 2022	SELL Open market or private sale	$431,100 $43.11 p/Share	10,000 Reduced 2.39%	409,124 Common Stock
May 16 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.33%	419,124 Common Stock
May 04 2022	SELL Open market or private sale	$394,300 $39.43 p/Share	10,000 Reduced 2.39%	409,124 Common Stock
May 04 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.33%	419,124 Common Stock

Also insider at

GMDA

Gamida Cell Ltd. Healthcare

Director

RIB

Robert I Blum

President & CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account